VB0 Stock Overview
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Viva Biotech Holdings Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.059 |
52 Week High | HK$0.21 |
52 Week Low | HK$0.052 |
Beta | 1.09 |
1 Month Change | -5.65% |
3 Month Change | -44.81% |
1 Year Change | -66.19% |
3 Year Change | -92.09% |
5 Year Change | n/a |
Change since IPO | -88.60% |
Recent News & Updates
Recent updates
Shareholder Returns
VB0 | DE Life Sciences | DE Market | |
---|---|---|---|
7D | 0.9% | 4.1% | 1.6% |
1Y | -66.2% | -5.0% | 6.4% |
Return vs Industry: VB0 underperformed the German Life Sciences industry which returned -3.7% over the past year.
Return vs Market: VB0 underperformed the German Market which returned 6.4% over the past year.
Price Volatility
VB0 volatility | |
---|---|
VB0 Average Weekly Movement | 12.8% |
Life Sciences Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VB0's share price has been volatile over the past 3 months.
Volatility Over Time: VB0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 2,271 | Chen Cheney Mao | https://www.vivabiotech.com.cn |
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure analysis of protein, and SPR technology; and PROTAC/molecular glue services. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins.
Viva Biotech Holdings Fundamentals Summary
VB0 fundamental statistics | |
---|---|
Market cap | €133.89m |
Earnings (TTM) | -€55.82m |
Revenue (TTM) | €308.77m |
0.4x
P/S Ratio-2.4x
P/E RatioIs VB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VB0 income statement (TTM) | |
---|---|
Revenue | CN¥2.41b |
Cost of Revenue | CN¥1.54b |
Gross Profit | CN¥876.68m |
Other Expenses | CN¥1.31b |
Earnings | -CN¥436.26m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.20 |
Gross Margin | 36.33% |
Net Profit Margin | -18.08% |
Debt/Equity Ratio | 78.9% |
How did VB0 perform over the long term?
See historical performance and comparison